Letter to the editor: GLP‑1RAs for pouchitis in obesity: what the current study does not tell us

To the Editors, We read with interest the report by Desai and colleagues that GLP‑1 receptor agonists were associated with a lower risk of recurrent pouchitis in obese patients with an ileal pouch–anal anastomosis and a history of pouchitis.1 The findings open an important avenue for secondary prophylaxis. Several unaddressed aspects, however, may help shape future investigations. The authors speculate that microbial stabilization may contribute to the protective effect, yet no direct evidence from pouch microbiota was provided. GLP‑1RAs can alter gut transit time, bile acid composition, and antimicrobial peptide secretion,2,3 each of which might reshape the pouch ecosystem in unpredictable ways. Without metagenomic or metabolomic profiling, the proposed mechanism remains conjectural. Future studies should collect pouch aspirates or effluent for shotgun sequencing alongside targeted analysis of short‑chain fatty acids and bile acids to clarify how the microbial community responds to treatment. Another underexplored issue concerns pouch motor function. GLP‑1RAs delay gastric emptying, but their impact on pouch contractility, residual rectal activity, or anal sphincter coordination is unknown. Some patients may experience incomplete evacuation, chronic constipation, or bacterial overgrowth, effects that would not be captured by a simple reduction in antidiarrheal use. Prospective research using pouch emptying scintigraphy or high‑resolution anorectal manometry could identify which patients benefit and who might develop adverse motor effects.4